<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03781219</url>
  </required_header>
  <id_info>
    <org_study_id>HL-085-102</org_study_id>
    <nct_id>NCT03781219</nct_id>
  </id_info>
  <brief_title>A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation</brief_title>
  <official_title>A Phase I, Single Arm, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of HL-085 Plus Vemurafenib in Patients With BRAF V600 Mutant Advanced Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Kechow Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Kechow Pharma, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, open-label, dose escalation study to evaluate tolerability, safety,
      pharmacokinetics and efficacy in patients with BRAF V600 mutant advanced solid tumor by
      HL-085 plus Vemurafenib treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>If no Dose-limiting toxicity (DLT) occurs in the first three subjects in Cycle 1, the dose will be escalated to the next dose level; If a DLT occurs in one of the first three subjects, three additional subjects will be enrolled for the same dose cohort, and undergo the same procedures. Dose -escalation is performed based on the scheduled dose groups until DLT occurs in two or more subjects in a dose group which consists of 3 or 6 subjects.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>up to 12 mouths</time_frame>
    <description>Number of Treatment-Related Adverse Events as Assessed by CTCAE v4.03 will be counted.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>HL-085 plus Vemurafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL-085 will be administered as BID with specified dose. And the Vemurafenib will be taken as the instruction in the label ( 960 mg, BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL-085</intervention_name>
    <description>HL-085 ( Capsule) is one MEK inhibitor.</description>
    <arm_group_label>HL-085 plus Vemurafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib</intervention_name>
    <description>Vemurafenib ( Tablet) is BRAF inhibitor,</description>
    <arm_group_label>HL-085 plus Vemurafenib</arm_group_label>
    <other_name>ZELBORAF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. BRAF V600 mutation in solid tumor.

          2. One measurable lesion as defined by RECIST 1.1 criteria for solid tumors.

          3. Chemotherapy, immunotherapy or radiotherapy ≥ 4 weeks prior to starting the study
             treatment.

          4. Surgery (except for tumor biopsy) or severe trauma ≤ 14 days prior to starting the
             study treatment.

          5. ECOG performance status of 0-1.

          6. Life expectancy ≥ 3 months.

          7. Ability to take the medicine orally.

          8. Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. Hypersensitivity to study drug ingredients or their analogues.

          2. Prior therapy with MEK-inhibitor.

          3. Receiving any other anti-cancer therapy at the same time .

          4. Active central nervous system (CNS) lesion.

          5. Bleeding symptoms at Grade 3 within 4 weeks prior to starting study treatment.

          6. ECG QTcB≥480msec in screening, or history of congenital long QT syndrome；

          7. Uncontrolled concomitant diseases or infectious diseases.

          8. Retinal diseases (Retinal Vein Occlusion (RVO) or Retinal pigment epithelial
             detachment (RPED) , et al.).

          9. History of HIV,HCV,HBV infection.

         10. Interstitial lung disease or interstitial pneumonitis, including clinically
             significant radiation pneumonitis will be excluded.

         11. Serum HCG test is positive.

         12. Other conditions that increase the risk of study and influence the result.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Liu, M.D,Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Kechow Pharma, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Liu, M.D,Ph.D</last_name>
    <phone>86 21 51323990</phone>
    <email>liuy@kechowpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Science</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuankai Shi, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Oncology Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henan Province Oncology Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital, Medicine School of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>December 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>December 19, 2018</last_update_submitted>
  <last_update_submitted_qc>December 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vemurafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

